Your shopping cart is currently empty

K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | In Stock | In Stock | |
| 5 mg | $80 | In Stock | In Stock | |
| 10 mg | $128 | In Stock | In Stock | |
| 25 mg | $289 | In Stock | In Stock | |
| 50 mg | $472 | In Stock | In Stock | |
| 100 mg | $693 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock | In Stock |
| Description | K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes. |
| In vitro | K6PC-5 (1-10 μM; 24 h) increases involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs), promotes differentiation and proliferation of keratinocytes via intracellular Ca2+ signaling, and stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase[1]. K6PC-5 (1-10 μM; 24 h) also promotes fibroblast proliferation and collagen synthesis in human fibroblasts, inducing intracellular Ca2+ concentration ([Ca2+]i) oscillations[2]. Additionally, K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV infection in EBOV-infected EA.hy926 cells, reduces virus titers in cell supernatants, and decreases VP40 levels in a concentration-dependent manner[3]. |
| In vivo | In intrinsically aged hairless mice (56 weeks old), topical application of 1% K6PC-5 for 2 weeks significantly increased the number of dermal fibroblasts and collagen production, resulting in a notable increase in dermal thickness[2]. |
| Synonyms | K6PC5, K6PC 5 |
| Molecular Weight | 343.5 |
| Formula | C19H37NO4 |
| Cas No. | 756875-51-1 |
| Smiles | CCCCCCCC(=O)C(CCCCCC)C(=O)NC(CO)CO |
| Relative Density. | 1.007 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 49 mg/mL (142.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (9.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.